To view this email as a web page, click here.
 
How Dangerous is Digoxin in AF?
Results of a post-hoc analysis of the ENGAGE-AF TIMI 48 trial show the answer could depend on a heart failure Dx.
What is your Rx for rate control?
 
VEGFI-induced Hypertension: How to Manage This New Syndrome?
Hypertension has been observed in every trial of antiangiogenic cancer therapy.
How should it be treated?
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.